This database contains 231 studies, archived under the term: "ADLs/IADLs"
Click here to filter this large number of results.
REMCARE: reminiscence groups for people with dementia and their family caregivers – effectiveness and cost-effectiveness pragmatic multicentre randomised trial
Woods, R. T.,
Bruce, E.,
Edwards, R. T.,
Elvish, R.,
Hoare, Z.,
Hounsome, B.,
Keady, J.,
Moniz-Cook, E. D.,
Orgeta, V.,
Orrell, M.,
Rees, J.,
Russell, I. T.
Objectives: The aim of the REMiniscence groups for people with dementia and their family CAREgivers (REMCARE) study was to assess the effectiveness and cost-effectiveness of joint reminiscence groups for people with dementia and their family caregivers as compared with usual care.; Design: A multicentre, pragmatic randomised controlled trial with two parallel arms – an intervention […]
Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trial
Cyarto, Elizabeth V.,
Lautenschlager, Nicola T.,
Desmond, Patricia M.,
Ames, David,
Szoeke, Cassandra,
Salvado, Olivier,
Sharman, Matthew J.,
Ellis, Kathryn A.,
Phal, Pramit M.,
Masters, Colin L.,
Rowe, Christopher C.,
Martins, Ralph N.,
Cox, Kay L.
Background: Older adults free of dementia but with subjective memory complaints (SMC) or mild cognitive impairment (MCI) are considered at increased risk of cognitive decline. Vascular risk factors (VRF), including hypertension, heart disease, smoking, hypercholesterolemia and lack of physical activity (PA) have been identified as modifiable risk factors contributing to cognitive decline, and white matter […]
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease
Objectives: To evaluate the safety of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in nondiabetic patients with Alzheimer disease (AD) and to explore treatment effect sizes on clinical outcomes.; Design: Double-blind, placebo-controlled randomized controlled trial of 18-month duration.; Setting: Two academic medical center outpatient clinics.; Patients: Nondiabetic patients meeting research criteria for probable AD were […]
Cognition and function in Alzheimer’s disease: identifying the transitions from moderate to severe disease
Background/aims: Cognitive and functional decline define the transition from moderate to severe Alzheimer’s disease (AD); however, specific relationships between deteriorating cognition and functional abilities are less well characterized. Such relationships are important in care planning and understanding patient needs. Objectives of this post hoc analysis of data from a multicenter randomized double-blind placebo-controlled study were […]